AR112348A1 - Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak - Google Patents
Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jakInfo
- Publication number
- AR112348A1 AR112348A1 ARP180102151A AR112348A1 AR 112348 A1 AR112348 A1 AR 112348A1 AR P180102151 A ARP180102151 A AR P180102151A AR 112348 A1 AR112348 A1 AR 112348A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- independently selected
- optionally
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: X¹ y X² se seleccionan, cada uno independientemente, entre N y CH; X³ se selecciona entre el grupo que consiste en N, CH, C-CH₃, C-CF₃, C-CHF₂, C-CH₂-O-CH₃, C-SMe, C-NMe₂, C-NH-CH₃, C-Cl, C-CN, y C-OMe; el resto de fórmula (2) se selecciona entre el grupo que consiste en los compuestos del grupo de fórmulas (3); Rᵃ, Rᵇ, Rᶜ, y Rᶠ se seleccionan, cada uno independientemente, entre el grupo que consiste en H y alquilo C₁₋₃; Rᵈ, Rᵉ, Rᵍ, Rʰ, Rⁱ, Rʲ, Rˡ, Rᵐ, Rⁿ y Rᵒ se seleccionan, cada uno independientemente, entre el grupo que consiste en H y alquilo C₁₋₃, en donde el grupo alquilo C₁₋₃ puede estar opcionalmente sustituido con 1 a 3 halógenos; opcionalmente, Rᵈ y Rᵉ pueden unirse para formar un anillo de ciclopropilo; A se selecciona entre el grupo que consiste en: (a) un grupo heterocíclico monocíclico de 4 a 10 miembros que contiene un átomo de nitrógeno y que opcionalmente contiene un heteroátomo adicional seleccionado entre N, S, S(O)₂ y O, y (b) un grupo heterocíclico multicíclico de 6 a 10 miembros que contiene un átomo de nitrógeno y que opcionalmente contiene un heteroátomo adicional seleccionado entre N, S, y O, en donde L está ligado a un átomo de carbono en A, y A está opcionalmente sustituido con 1 a 3 grupos Rᵏ; cada Rᵏ se selecciona independientemente entre el grupo que consiste en F, CN, alcoxi C₁₋₃, ciclopropilo, y alquilo C₁₋₃, en donde el grupo alquilo C₁₋₃ puede estar opcionalmente sustituido con OH, OMe o 1 a 3 halógenos; R¹ se selecciona entre el grupo que consiste en los compuestos del grupo de fórmulas (4), en donde Rᵖ y Rq se seleccionan, cada uno independientemente, entre el grupo que consiste en H, cicloalquilo C₃₋₅ y alquilo C₁₋₆, en donde el grupo alquilo C₁₋₆ puede estar opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en alcoxi C₁₋₃ y -S-alquilo C₁₋₃, o Rᵖ y Rq forman un grupo heterocíclico monocíclico de 4 a 6 miembros que contiene un átomo de nitrógeno y que opcionalmente contiene un heteroátomo adicional seleccionado entre N, S, y O, en donde el grupo heterocíclico monocíclico de 4 a 6 miembros está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en alquilo C₁₋₆, alcoxi C₁₋₃, -S-alquilo C₁₋₃ y alquilo C₁₋₃-alcoxi C₁₋₃; R² se selecciona entre el grupo que consiste en H, Cl, OMe, Me y F; R³ se selecciona entre el grupo que consiste en H y F; R⁴ se selecciona entre el grupo que consiste en H y F; y R⁵ se selecciona entre el grupo que consiste en H, Me y F.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539642P | 2017-08-01 | 2017-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112348A1 true AR112348A1 (es) | 2019-10-16 |
Family
ID=63209687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102151 AR112348A1 (es) | 2017-08-01 | 2018-07-31 | Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak |
Country Status (23)
Country | Link |
---|---|
US (4) | US10392368B2 (es) |
EP (1) | EP3652169A1 (es) |
JP (2) | JP7098716B2 (es) |
KR (1) | KR20200036004A (es) |
CN (1) | CN111032646B (es) |
AR (1) | AR112348A1 (es) |
AU (1) | AU2018312349A1 (es) |
BR (1) | BR112020002265A2 (es) |
CA (1) | CA3069990A1 (es) |
CL (1) | CL2020000283A1 (es) |
CO (1) | CO2020001469A2 (es) |
EA (1) | EA038912B1 (es) |
IL (1) | IL272031A (es) |
MA (1) | MA49570A (es) |
MX (1) | MX2020001170A (es) |
MY (1) | MY200629A (es) |
PE (1) | PE20201028A1 (es) |
PH (1) | PH12020500201A1 (es) |
SG (1) | SG11202000602YA (es) |
TW (1) | TW201920150A (es) |
UA (1) | UA125318C2 (es) |
WO (1) | WO2019027960A1 (es) |
ZA (1) | ZA202000561B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111032646B (zh) | 2017-08-01 | 2023-01-03 | 施万生物制药研发Ip有限责任公司 | 作为jak激酶抑制剂的吡唑并和三唑并双环化合物 |
JP2022518741A (ja) | 2019-01-23 | 2022-03-16 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | JAKキナーゼ阻害剤としてのイミダゾ[1,5-a]ピリジン、1,2,4-トリアゾロ[4,3-a]ピリジンおよびイミダゾ[1,5-a]ピラジン |
JP2022541013A (ja) * | 2019-07-15 | 2022-09-21 | ノバルティス アーゲー | 肝臓x受容体アゴニストでマイボーム腺機能不全を治療するための方法 |
EP4149462A4 (en) * | 2020-05-14 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | ADMINISTRATION OF A GUT SELECTIVE JAK3 INHIBITOR |
CN114075221B (zh) * | 2020-08-13 | 2024-08-23 | 广东东阳光药业股份有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CN114075220A (zh) * | 2020-08-13 | 2022-02-22 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2022053000A1 (zh) * | 2020-09-10 | 2022-03-17 | 四川海思科制药有限公司 | 一种碳环酰胺衍生物及其在医药上的应用 |
WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
EP4313974A1 (en) * | 2021-03-29 | 2024-02-07 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
CN113061137B (zh) * | 2021-04-02 | 2022-08-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
US20220378746A1 (en) * | 2021-05-03 | 2022-12-01 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
WO2023116748A1 (zh) * | 2021-12-23 | 2023-06-29 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR034588A1 (es) | 2001-04-20 | 2004-03-03 | Wyeth Corp | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
KR100976076B1 (ko) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
WO2007050574A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
JP2009532375A (ja) | 2006-03-30 | 2009-09-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
KR100834758B1 (ko) | 2006-07-05 | 2008-06-05 | 삼성전자주식회사 | 컴퓨터 시스템 보안 장치 및 방법 |
JP2009007342A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
US8658635B2 (en) | 2008-06-05 | 2014-02-25 | Glaxosmithkline Intellectual Property Development Limited | Benzpyrazol derivatives as inhibitors of PI3 kinases |
WO2010012121A1 (zh) | 2008-07-28 | 2010-02-04 | 江苏国华投资有限公司 | 芳烷基哌啶(嗪)衍生物及其在治疗精神分裂症中的应用 |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
PT2635299T (pt) | 2010-11-02 | 2019-10-14 | Univ Columbia | Métodos de tratamento de distúrbios de perda de cabelo |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3,4-b]吡啶-4-羧酸酰胺衍生物 |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CN104334191A (zh) | 2012-03-29 | 2015-02-04 | 纽约市哥伦比亚大学托管会 | 治疗毛发脱落疾病的方法 |
WO2013167403A1 (en) * | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
TWI629275B (zh) | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 |
CN106061973B (zh) | 2013-12-05 | 2019-07-09 | 辉瑞公司 | 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺 |
CA2937111A1 (en) | 2014-01-24 | 2015-07-30 | Abbvie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
AU2015222865B2 (en) * | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
WO2015173683A1 (en) | 2014-05-14 | 2015-11-19 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
US10519160B2 (en) | 2014-07-18 | 2019-12-31 | The General Hospital Corporation | Imaging agents for neural flux |
US10590086B2 (en) | 2014-11-03 | 2020-03-17 | Iomet Pharma Ltd. | Pharmaceutical compound |
CN105837574B (zh) | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
CA2984183C (en) | 2015-05-01 | 2021-11-09 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
EP3291794A4 (en) | 2015-05-07 | 2019-02-13 | The Trustees of Columbia University in the City of New York | METHODS AND COMPOSITIONS FOR PROMOTING HAIR GROWTH |
EP3865481A1 (en) | 2015-11-03 | 2021-08-18 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
SG11201811470PA (en) | 2016-06-30 | 2019-01-30 | Daewoong Pharmaceutical Co Ltd | Pyrazolopyrimidine derivatives as kinase inhibitor |
WO2018049174A1 (en) | 2016-09-08 | 2018-03-15 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
US20180117148A1 (en) | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN111032646B (zh) | 2017-08-01 | 2023-01-03 | 施万生物制药研发Ip有限责任公司 | 作为jak激酶抑制剂的吡唑并和三唑并双环化合物 |
AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
HRP20221043T1 (hr) | 2017-12-28 | 2022-11-11 | Daewoong Pharmaceutical Co., Ltd. | Derivat oksi-fluoropiperidina kao inhibitor kinaze |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
JP2022518741A (ja) * | 2019-01-23 | 2022-03-16 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | JAKキナーゼ阻害剤としてのイミダゾ[1,5-a]ピリジン、1,2,4-トリアゾロ[4,3-a]ピリジンおよびイミダゾ[1,5-a]ピラジン |
EP4149462A4 (en) * | 2020-05-14 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | ADMINISTRATION OF A GUT SELECTIVE JAK3 INHIBITOR |
-
2018
- 2018-07-31 CN CN201880050675.3A patent/CN111032646B/zh active Active
- 2018-07-31 TW TW107126579A patent/TW201920150A/zh unknown
- 2018-07-31 PE PE2020000171A patent/PE20201028A1/es unknown
- 2018-07-31 JP JP2020505224A patent/JP7098716B2/ja active Active
- 2018-07-31 KR KR1020207005956A patent/KR20200036004A/ko not_active Application Discontinuation
- 2018-07-31 MA MA049570A patent/MA49570A/fr unknown
- 2018-07-31 EP EP18755621.2A patent/EP3652169A1/en not_active Withdrawn
- 2018-07-31 AU AU2018312349A patent/AU2018312349A1/en not_active Abandoned
- 2018-07-31 UA UAA202001352A patent/UA125318C2/uk unknown
- 2018-07-31 MX MX2020001170A patent/MX2020001170A/es unknown
- 2018-07-31 MY MYPI2020000251A patent/MY200629A/en unknown
- 2018-07-31 WO PCT/US2018/044508 patent/WO2019027960A1/en active Application Filing
- 2018-07-31 CA CA3069990A patent/CA3069990A1/en not_active Abandoned
- 2018-07-31 SG SG11202000602YA patent/SG11202000602YA/en unknown
- 2018-07-31 US US16/050,227 patent/US10392368B2/en active Active
- 2018-07-31 AR ARP180102151 patent/AR112348A1/es unknown
- 2018-07-31 EA EA202090413A patent/EA038912B1/ru unknown
- 2018-07-31 BR BR112020002265-9A patent/BR112020002265A2/pt not_active Application Discontinuation
-
2019
- 2019-06-28 US US16/456,179 patent/US10538513B2/en active Active
- 2019-11-19 US US16/688,109 patent/US10968205B2/en active Active
-
2020
- 2020-01-14 IL IL272031A patent/IL272031A/en unknown
- 2020-01-27 PH PH12020500201A patent/PH12020500201A1/en unknown
- 2020-01-28 ZA ZA2020/00561A patent/ZA202000561B/en unknown
- 2020-01-31 CL CL2020000283A patent/CL2020000283A1/es unknown
- 2020-02-11 CO CONC2020/0001469A patent/CO2020001469A2/es unknown
-
2021
- 2021-02-22 US US17/249,128 patent/US20220119369A1/en not_active Abandoned
- 2021-03-17 JP JP2021043173A patent/JP2021098751A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CO2020001469A2 (es) | 2020-05-29 |
JP2021098751A (ja) | 2021-07-01 |
US20200216423A1 (en) | 2020-07-09 |
JP7098716B2 (ja) | 2022-07-11 |
MA49570A (fr) | 2020-05-20 |
US20190315724A1 (en) | 2019-10-17 |
UA125318C2 (uk) | 2022-02-16 |
EP3652169A1 (en) | 2020-05-20 |
IL272031A (en) | 2020-03-31 |
KR20200036004A (ko) | 2020-04-06 |
TW201920150A (zh) | 2019-06-01 |
US20190040043A1 (en) | 2019-02-07 |
US10392368B2 (en) | 2019-08-27 |
SG11202000602YA (en) | 2020-02-27 |
EA202090413A1 (ru) | 2020-06-24 |
ZA202000561B (en) | 2022-04-28 |
WO2019027960A1 (en) | 2019-02-07 |
CN111032646B (zh) | 2023-01-03 |
PH12020500201A1 (en) | 2020-10-12 |
MX2020001170A (es) | 2020-03-12 |
AU2018312349A1 (en) | 2020-02-06 |
BR112020002265A2 (pt) | 2020-07-28 |
EA038912B1 (ru) | 2021-11-09 |
MY200629A (en) | 2024-01-06 |
CN111032646A (zh) | 2020-04-17 |
CA3069990A1 (en) | 2019-02-07 |
PE20201028A1 (es) | 2020-10-05 |
CL2020000283A1 (es) | 2020-06-12 |
US10538513B2 (en) | 2020-01-21 |
US20220119369A1 (en) | 2022-04-21 |
JP2020529987A (ja) | 2020-10-15 |
US10968205B2 (en) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112348A1 (es) | Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
AR100059A1 (es) | Compuestos útiles como inmunomoduladores | |
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
AR097279A1 (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx | |
AR088801A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
AR093921A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x7 | |
AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
AR109964A1 (es) | Derivados de aril-sulfonamidas como bloqueadores del canal de sodio | |
AR099999A1 (es) | Inhibidores macrocíclicos de quinasas cdk9 con actividad antiproliferativa mejorada | |
AR100439A1 (es) | Derivados de carboxamida | |
AR111941A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
AR102480A1 (es) | ALCOHOLES TRIFLUOROMETÍLICOS COMO MODULADORES DE RORgt | |
AR105929A1 (es) | Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |